| Autor: |
Laohaprasit V; Department of Neurological Surgery, University of Washington, Seattle., Edwards MW, Mayberg MR |
| Jazyk: |
angličtina |
| Zdroj: |
Neurosurgery [Neurosurgery] 1993 Apr; Vol. 32 (4), pp. 630-3; discussion 633-4. |
| DOI: |
10.1227/00006123-199304000-00021 |
| Abstrakt: |
Factor XIII is an endogenous clotting factor that retards thrombus degradation by cross-linking fibrin. To determine the efficacy of Factor XIII as a topical clot-stabilizing agent in preventing postoperative hemorrhage associated with coagulopathy, a rat model of experimental craniotomy and standardized bilateral frontal corticectomy was developed. In 25 rats (50 lesions), recombinant human Factor XIII or placebo solution was topically applied to corticectomy cavities after hemostasis was achieved; each animal served as its own control. In 20 rats, heparin sulfate (100 U/kg.h) was initiated intraperitoneally 3 days after surgery and was continually administered by an Alzet pump for 7 days, compared with a control group of 5 rats receiving saline intraperitoneally. The volume of intracranial hemorrhage was quantitatively determined from coronal sections by use of automated image analysis. Large (> 50 mm3) intracerebral hemorrhages were significantly more frequent in placebo (60%)- compared with recombinant Factor XIII (15%)-treated lesions (P < 0.01) in animals receiving heparin. The topical application of clot-stabilizing agents such as Factor XIII may reduce the risk of postoperative intracranial hemorrhage, especially in high-risk patients with coagulopathy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
